6
Participants
Start Date
March 19, 2020
Primary Completion Date
April 14, 2023
Study Completion Date
April 28, 2023
Combination Product: Nivolumab with Pemetrexed
Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly. Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days. Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.
Cross Cancer Institute, Edmonton
Alberta Cancer Foundation
OTHER
AHS Cancer Control Alberta
OTHER